6.50Open4.11Pre Close29 Volume17 Open Interest40.50Strike Price17.17KTurnover226.24%IV-2.78%PremiumMay 9, 2025Expiry Date6.64Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9545Delta0.0276Gamma5.05Leverage Ratio-0.2051Theta-0.0007Rho-4.82Eff Leverage0.0015Vega
TG Therapeutics Stock Discussion
TG Therapeutics Crushes Earnings: MS Drug BRIUMVI Drives 137% Growth, Company Turns Profitable
Game-Changing MS Treatment? BRIUMVI Single-Dose Trial Reveals Breakthrough Potential
Game-Changing MS Treatment: BRIUMVI Reveals Exceptional Real-World Safety Profile
Medical Journals Reveal Breakthrough: BRIUMVI Succeeds Where Other MS Treatments Fall Short
How TG Therapeutics Transformed from Clinical-Stage to Profitable Biotech with 250% Revenue Growth
Can BRIUMVI Succeed Where Other MS Treatments Failed? New Clinical Data Reveals Promising Results
Larger Image: tradingview.com...
$TG Therapeutics (TGTX.US)$
No comment yet